Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis

被引：0
|
作者：
Anne Bertrand
Marie Kostine
Thomas Barnetche
Marie-Elise Truchetet
Thierry Schaeverbeke
机构：
[1] Département de Rhumatologie,Laboratoire d’Immunologie, UMR
[2] Hôpital Pellegrin,CNRS 5164
[3] CHU de Bordeaux,Unité sous Contrat, Infections à Mycoplasmes et à Chlamydia chez l’Homme
[4] Université de Bordeaux,undefined
[5] Université de Bordeaux,undefined
来源：
BMC Medicine | / 13卷
关键词：
Anti-CTLA4 antibodies; Colitis; Dermatitis; Hypohysitis; Immune related adverse events; Ipilimumab; Metastatic tumors; Oncology; Tremelimumab;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] The safety and tolerability of combined immune checkpoint inhibitors (anti-PD-1/PD-L1 plus anti-CTLA-4): a systematic review and meta-analysis
    Gu, Lihu
    Khadaroo, Parikshit Asutosh
    Su, Hui
    Kong, Liya
    Chen, Liangliang
    Wang, Xianfa
    Li, Xinlong
    Zhu, Hepan
    Zhong, Xin
    Pan, Junhai
    Chen, Manman
    BMC CANCER, 2019, 19 (1)
  • [22] Potential Immune-Related Adverse Events Associated With Monotherapy and Combination Therapy of Ipilimumab, Nivolumab, and Pembrolizumab for Advanced Melanoma: A Systematic Review and Meta-Analysis
    Almutairi, Abdulaali R.
    McBride, Ali
    Slack, Marion
    Erstad, Brian L.
    Abraham, Ivo
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [23] Treatment-related adverse events of immune checkpoint inhibitors in clinical trials: a systematic review and meta-analysis
    Shen, Xin
    Yang, Jun
    Qian, Geng
    Sheng, Mingyu
    Wang, Yu
    Li, Guohui
    Yan, Jiaqing
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [24] Association of Immune Checkpoint Inhibitors With Neurologic Adverse Events A Systematic Review and Meta-analysis
    Farooq, Muhammad Zain
    Aqeel, Sheeba Ba
    Lingamaneni, Prasanth
    Pichardo, Rayli Carolina
    Jawed, Aleeza
    Khalid, Saad
    Banskota, Shristi Upadhyay
    Fu, Pingfu
    Mangla, Ankit
    JAMA NETWORK OPEN, 2022, 5 (04)
  • [25] Incidence and Risk of Hematological Adverse Events Associated With Immune Checkpoint Inhibitors: A Systematic Literature Review and Meta-Analysis
    Ohashi, Takuma
    Takase-Minegishi, Kaoru
    Maeda, Ayaka
    Hamada, Naoki
    Yoshimi, Ryusuke
    Kirino, Yohei
    Teranaka, Hiroshi
    Kunimoto, Hiroyoshi
    Hagihara, Maki
    Matsumoto, Kenji
    Namkoong, Ho
    Horita, Nobuyuki
    Nakajima, Hideaki
    JOURNAL OF HEMATOLOGY, 2023, 12 (02) : 66 - 74
  • [26] Immune-related adverse events associated with nab-paclitaxel/paclitaxel combined with immune checkpoint inhibitors: a systematic review and network meta-analysis
    Hao, Wenjing
    Zhang, Jun
    Wang, Yunxia
    Fang, Boyu
    Jin, Shasha
    Yuan, Jing
    Cai, Weimin
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [27] Immune Checkpoint Inhibitors and Immune-Related Adverse Events in Patients With Advanced Melanoma A Systematic Review and Network Meta-analysis
    Chang, Ching-Yuan
    Park, Haesuk
    Malone, Daniel C.
    Wang, Ching-Yu
    Wilson, Debbie L.
    Yeh, Yu-Min
    Van Boemmel-Wegmann, Sascha
    Lo-Ciganic, Wei-Hsuan
    JAMA NETWORK OPEN, 2020, 3 (03)
  • [28] Anti-PD-1/L1-associated immune-related adverse events as harbinger of favorable clinical outcome: systematic review and meta-analysis
    R. Park
    L. Lopes
    A. Saeed
    Clinical and Translational Oncology, 2021, 23 : 100 - 109
  • [29] Anti-PD-1/L1-associated immune-related adverse events as harbinger of favorable clinical outcome: systematic review and meta-analysis
    Park, R.
    Lopes, L.
    Saeed, A.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2021, 23 (01) : 100 - 109
  • [30] Uncoupling therapeutic from immunotherapy-related adverse effects for safer and effective anti-CTLA-4 antibodies in CTLA4 humanized mice
    Xuexiang Du
    Mingyue Liu
    Juanjuan Su
    Peng Zhang
    Fei Tang
    Peiying Ye
    Martin Devenport
    Xu Wang
    Yan Zhang
    Yang Liu
    Pan Zheng
    Cell Research, 2018, 28 : 433 - 447
12345